Upstream Bio to reveal Phase 2 trial results for asthma drug

Upstream Bio to reveal Phase 2 trial results for asthma drug
Upstream Bio trial results

Upstream Bio has announced it will host a webcast to release the top-line results of its Phase 2 VALIANT trial for the drug verekitug, aimed at treating severe asthma.

The webcast is scheduled for tomorrow morning at 8:00 a.m. ET. This strategic communication focuses on the pharmaceutical company's efforts to advance treatment options for asthma patients.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.